Matthew P. Giannetti, MD, assistant professor, Harvard Medical School, Boston, Massachusetts, describes clonal and non-clonal mast cell activation disorders, and the relationship to the diagnosis of systemic mastocytosis. Dr Giannetti also reviews recent guideline updates that delineate the activation of mast cells as an acute event versus a chronic process.
Systemic mastocytosis, a rare blood disorder, affects the entire body. There are many challenges associated with living with this systemic mastocytosis that are centered around reducing the frequency…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
In an interview conducted at the 2024 Congress of the European Hematology Association in Madrid, Spain, Lindsay Rein, MD, Duke University Medical Center, Durham, North Carolina, provided insights…
